Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Decreases By 60.0%

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 1,000 shares, a decrease of 60.0% from the October 15th total of 2,500 shares. Based on an average daily volume of 3,300 shares, the short-interest ratio is currently 0.3 days.

enGene Stock Performance

Shares of ENGNW traded up $0.06 during trading hours on Friday, reaching $1.51. The company had a trading volume of 12,682 shares, compared to its average volume of 19,480. The firm has a 50 day simple moving average of $1.70 and a 200-day simple moving average of $1.79. enGene has a 12-month low of $0.40 and a 12-month high of $6.50.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.